Haleon Us Holdings patents expiration
1. Abreva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5534554 | HALEON US HOLDINGS | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(10 years ago) | |
| US4874794 | HALEON US HOLDINGS | Inflammatory disease treatment |
Apr, 2014
(10 years ago) | |
Drugs and Companies using DOCOSANOL ingredient
Market Authorisation Date: 25 July, 2000
Treatment: Treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching
Dosage: CREAM;TOPICAL
ABREVA family patents
2. Advil Allergy Sinus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863287 | HALEON US HOLDINGS | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(2 years from now) | |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
ADVIL ALLERGY SINUS family patents
3. Advil Dual Action With Acetaminophen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11918693 | HALEON US HOLDINGS | Ibuprofen and acetaminophen tablet |
Jul, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 28, 2023 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient
Market Authorisation Date: 28 February, 2020
Treatment: NA
Dosage: TABLET;ORAL
ADVIL DUAL ACTION WITH ACETAMINOPHEN family patents
4. Advil Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883849 | HALEON US HOLDINGS | Treatment of sleep disturbances |
Jan, 2022
(2 years ago) | |
| US9155718 | HALEON US HOLDINGS | Treatment of sleep disturbances |
Jan, 2022
(2 years ago) | |
Drugs and Companies using DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient
Dosage: CAPSULE;ORAL
ADVIL PM family patents
5. Advil Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263647 | HALEON US HOLDINGS | Treatment of sleep disturbances |
May, 2022
(1 year, 11 months ago) | |
Drugs and Companies using DIPHENHYDRAMINE CITRATE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: NA
Dosage: TABLET;ORAL
ADVIL PM family patents
6. Alli patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004996 | HALEON US HOLDINGS | Tetrahydrolipstatin containing compositions |
Jan, 2018
(6 years ago) | |
Drugs and Companies using ORLISTAT ingredient
Market Authorisation Date: 07 February, 2007
Treatment: NA
Dosage: CAPSULE;ORAL
ALLI family patents
7. Children's Advil Allergy Sinus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | HALEON US HOLDINGS | Pharmaceutical suspension composition |
May, 2024
(22 days from now) | |
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ADVIL ALLERGY SINUS family patents
8. Children's Advil-flavored patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | HALEON US HOLDINGS | Pharmaceutical suspension composition |
May, 2024
(22 days from now) | |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ADVIL-FLAVORED family patents
9. Excedrin (migraine Relief) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972916 | HALEON US HOLDINGS | Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
Jul, 2017
(6 years ago) | |
Drugs and Companies using ACETAMINOPHEN; ASPIRIN; CAFFEINE ingredient
Market Authorisation Date: 14 January, 1998
Treatment: Treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia nausea and functional disability
Dosage: TABLET;ORAL
EXCEDRIN (MIGRAINE RELIEF) family patents
10. Flonase Sensimist Allergy Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | HALEON US HOLDINGS | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7541350 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | HALEON US HOLDINGS | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8752543 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8062264 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | HALEON US HOLDINGS | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | HALEON US HOLDINGS | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED;NASAL
FLONASE SENSIMIST ALLERGY RELIEF family patents
11. Nicorette patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323683 | HALEON US HOLDINGS | Flavoring of drug-containing chewing gums |
Apr, 2028
(3 years from now) | |
| US8940772 | HALEON US HOLDINGS | Nicotine lozenge composition |
Apr, 2029
(4 years from now) | |
| US8501164 | HALEON US HOLDINGS | Nicotine lozenge compositions |
Jun, 2029
(5 years from now) | |
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: TROCHE/LOZENGE;ORAL
NICORETTE family patents